Patents by Inventor Guido Galley

Guido Galley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11319314
    Abstract: The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Stefan Berchtold, Guido Galley, Annick Goergler, Roland Jakob-Roetne, Daniela Krummenacher, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Rosa Maria Rodriguez Sarmiento, Christian Schnider
  • Patent number: 11312711
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: April 26, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
  • Publication number: 20210309653
    Abstract: The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, i-f two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(0)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof.
    Type: Application
    Filed: November 6, 2017
    Publication date: October 7, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Stefan BERCHTOLD, Guido GALLEY, Annick GOERGLER, Roland JAKOB-ROETNE, Daniela KRUMMENACHER, Anja LIMBERG, Werner NEIDHART, Hasane RATNI, Michael REUTLINGER, Rosa Maria RODRIGUEZ SARMIENTO, Christian SCHNIDER
  • Publication number: 20210122743
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Application
    Filed: June 11, 2020
    Publication date: April 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Marius HOENER, Roger NORCROSS, Philippe PFLIEGER
  • Publication number: 20200291034
    Abstract: The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, —CH2—C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Hasane RATNI, Karlheinz BAUMANN, Guido GALLEY, Georg JAESCHKE, Roland JAKOB-ROETNE, Anja LIMBERG, Werner NEIDHART, Rosa Maria RODRIGUEZ-SARMIENTO
  • Patent number: 10604517
    Abstract: The present invention relates to compounds of formula hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or two neighboring carbon atoms may form on phenyl an additional ring containing —O—CH2—O—; n is 1 to 5; R2 is hydrogen or lower alkyl substituted by halogen; R3 is hydrogen or lower alkyl substituted by halogen; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers or optical isomers or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: March 31, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karlheinz Baumann, Guido Galley, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Rosa Maria Rodriguez Sarmiento, Björn Bartels, Hasane Ratni
  • Patent number: 10562903
    Abstract: The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, —CH2—C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Hasane Ratni, Karlheinz Baumann, Guido Galley, Georg Jaeschke, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Rosa Maria Rodriguez-Sarmiento
  • Patent number: 10508107
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: December 17, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
  • Patent number: 10398702
    Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 3, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Guido Galley, Roger Norcross, Nicolas Zorn
  • Patent number: 10316036
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Publication number: 20190134050
    Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Alexander FLOHR, Guido GALLEY, Roger NORCROSS, Nicolas ZORN
  • Publication number: 20190010156
    Abstract: The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, —CH2—C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Hasane RATNI, Karlheinz BAUMANN, Guido GALLEY, Georg JAESCHKE, Roland JAKOB-ROETNE, Anja LIMBERG, Werner NEIDHART, Rosa Maria RODRIGUEZ-SARMIENTO
  • Publication number: 20190010148
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
  • Publication number: 20180237432
    Abstract: The present invention relates to compounds of formula hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or two neighboring carbon atoms may form on phenyl an additional ring containing —O—CH2—O—; n is 1 to 5; R2 is hydrogen or lower alkyl substituted by halogen; R3 is hydrogen or lower alkyl substituted by halogen; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers or optical isomers or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
    Type: Application
    Filed: March 6, 2018
    Publication date: August 23, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Karlheinz Baumann, Guido Galley, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Rosa Maria Rodriguez Sarmiento, Björn Bartels, Hasane Ratni
  • Patent number: 10023559
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1. R2, R2?, R3, R4, R5, L1, L2 and N are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 17, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Philippe Pflieger, Etienne Rauber
  • Patent number: 9957261
    Abstract: The present invention relates to compounds TAAR receptor antagonists of formula I wherein X, R, L, Ar and R1 are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: May 1, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Annick Goergler, Roger Norcross, Philippe Pflieger, Alina Tirla, Philipp Schmid
  • Publication number: 20180037582
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Patent number: 9840501
    Abstract: The present invention relates to compounds of formula of formula I wherein X, R, L, Ar, R1 and n are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 12, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guido Galley, Philippe Pflieger, Roger Norcross, Giuseppe Cecere, Hong Shen, Yimin Hu
  • Patent number: 9828374
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Patent number: 9790230
    Abstract: The present invention relates to compounds of formula of formula I wherein X, L and R1 are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: October 17, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Yimin Hu, Roger Norcross, Philippe Pflieger, Hong Shen